ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2025
Stability Study of Lorazepam Oral Solution Repackaged in Amber Colored ENFit Oral Syringes.
Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLorazepam is a benzodiazepine drug that hospital pharmacies commonly dispense to treat patients with severe anxiety and seizure disorders. Lorazepam oral concentrate, a marketed oral formulation of lorazepam, contains polyethylene glycol and propylene glycol in a solution (2 mg/mL). At Strong Memorial Hospital nurses draw patient-specific doses from a 30mL bulk bottle of lorazepam oral concentrate for administration. This study aims to investigate the stability of lorazepam when stored in repackaged amber-colored ENFit Oral syringes under typical hospital pharmacy conditions (stored at ambient temperature), to reduce waste.
methodsStability indicating HPLC assay was established to investigate the degradation profile of lorazepam treated at ambient temperature (∼25°C) and hot conditions (60°C) under acidic (1N HCL), basic (1N NaOH), and oxidative (H
resultsAfter 182 days, both volumes (0.25 mL and 0.5 mL) of lorazepam repackaged formulation in the ENFit oral syringes, exhibited no visible changes and remained within the acceptable concentration range (100 ± 10%) when stored at ambient temperature (72 ± 4°F). The stability data demonstrated that lorazepam repackaged in amber-colored ENFit Oral Syringes remained stable at room temperature for up to 90 days.
conclusionThis study represents a 30-day extension in the stability compared with the previously reported 60-day stability period for the repackaged lorazepam oral syringes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.